Patients with IPF experience similar 48-week FVC declines with pamrevlumab, placebo

SAN DIEGO — The absolute change in FVC at 48 weeks was similar between patients with idiopathic pulmonary fibrosis receiving pamrevlumab vs. placebo, according to a presentation at the American Thoracic Society International Conference.Pamrevlumab (FibroGen) is a fully human monoclonal antibody that impedes connective tissue growth factor, according to researchers.

Related Keywords

United States ,American ,Ganesh Raghu ,Kristen Dowd ,Byisabella Hornick ,Pamrevlumab Fibrogen ,University Of Washington Uw Medicine ,American Thoracic Society International Conference ,University Of California San Diego ,American Thoracic Society International ,Scleroderma Clinic ,Respiratory Questionnaire ,California San Diego Shortness ,Breath Questionnaire ,Leicester Cough Questionnaire ,